Desai Arjun JJ
CIK: 0001982985
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TriSalus Stock Rises After FDA Clears TriNav Advance. TriSalus Life Sciences shares climbed 15.6% following FDA clearance for its TriNav Advance product. This regulatory approval marks a significant milestone for the company's pipeline. The stock is currently testing key support levels after the recent price movement.
Transaction History
| LGVN | ▲ Buy | Grant | 36,000 | $0 | 8/19/2026 | View on chart |
| TLSI | ▼ Sell | Open Market | 30,000 | $111K | 12/10/2024 | View on chart |
| TLSI | ▲ Buy | Grant | 74,000 | — | 7/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Longeveron to speak at three longevity investment conferences
Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.
Longeveron to speak at three longevity investment conferences. Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.